Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

Waldenstrom macroglobulinemia.

Xavier Leleu¹, Aldo M Roccaro, Anne-Sophie Moreau

¹Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.

|June 17, 2008

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myeloma.

Blood advances·2026

Same author

Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece.

Annals of hematology·2026

Same author

Characterization and outcomes of severe complications after autologous hematopoietic stem-cell transplantation: a retrospective multicenter study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Same author

Dyspnea as a marker of prognosis in immunocompromised patients with acute respiratory failure.

Annals of intensive care·2026

Same author

Epidemiology, ventilation, and outcomes of acute respiratory failure in immunocompromised patients from 103 intensive care units in 26 countries: a retrospective observational study.

The Lancet. Respiratory medicine·2026

Same author

Technical feasibility of hyperbaric oxygen therapy for gas embolism with ECMO support: a brief report.

Critical care (London, England)·2026

New developments in Waldenstrom Macroglobulinemia (WM) biology have led to novel therapeutic agents. Research is exploring targeted treatments for this incurable B-cell malignancy, offering hope for improved patient outcomes.

Area of Science:

Hematology
Oncology
Immunology

Background:

Waldenstrom Macroglobulinemia (WM) is an incurable B-cell malignancy.
Characterized by bone marrow infiltration and IgM monoclonal gammopathy.
Current therapies offer limited median survival, necessitating novel treatment approaches.

Purpose of the Study:

To review recent advances in understanding WM biology.
To highlight novel therapeutic agents in preclinical and clinical development for WM.
To discuss targeted strategies for treating WM.

Main Methods:

Review of preclinical studies and clinical trials.
Analysis of novel agents targeting WM-specific pathways.
Exploration of emerging therapeutic classes including proteasome inhibitors, Akt/mTor inhibitors, and immunomodulatory agents.

More Related Videos

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Related Experiment Videos

Last Updated: Jul 4, 2026

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Main Results:

Several novel agents show promise in preclinical and early clinical studies.
Targeted therapies include bortezomib, perifosine, Rad001, thalidomide, and lenalidomide.
Monoclonal antibodies and other agents like enzastaurin and resveratrol are under investigation.

Conclusions:

Advances in WM biology are driving the development of targeted therapies.
Novel agents offer potential for improved treatment outcomes in WM.
Ongoing research is crucial for developing effective and curative strategies for WM.